Evidence map›Paper›PMID 34366942›Full record

ArticleFrontiers in psychiatry2021

Case Report: CBD Cigarettes for Harm Reduction and Adjunctive Therapy in a Patient With Schizophrenia and Substance Use Disorder.

Maximilian Meyer, Marc Walter, Stefan Borgwardt, Alexandra Scheidegger, Elisabeth Lang, Patrick Köck

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Maximilian MeyerDepartment of Psychiatry (Universitäre Psychiatrische Kliniken), University of Basel, Basel, Switzerland.
Marc WalterDepartment of Psychiatry (Universitäre Psychiatrische Kliniken), University of Basel, Basel, Switzerland.
Stefan BorgwardtDepartment of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany.
Alexandra ScheideggerDepartment of Psychiatry (Universitäre Psychiatrische Kliniken), University of Basel, Basel, Switzerland.
Elisabeth LangDepartment of Psychiatry (Universitäre Psychiatrische Kliniken), University of Basel, Basel, Switzerland.
Patrick KöckDepartment of Psychiatry (Universitäre Psychiatrische Kliniken), University of Basel, Basel, Switzerland.
Universitäre Psychiatrische Kliniken Basel · CHUniversity of Basel · CHUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of patients with schizophrenia and substance use disorder poses a challenge for clinicians. Continued use of cannabis and cocaine can exacerbate psychotic symptoms and worsen the course of disease. To date, no pharmacotherapy is available for patients with cannabis use disorder (CUD). Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the main active constituents in

Indexed as

cannabidiolcase reportpsychosisschizophreniasubstance use disorder

Identifiers

PMID34366942
PMCPMC8339295
OpenAlexW3186070261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.